These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 25885326

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue.
    Calza L, Manfredi R, Colangeli V, Pocaterra D, Rosseti N, Pavoni M, Chiodo F.
    AIDS Patient Care STDS; 2009 Sep; 23(9):691-7. PubMed ID: 19739937
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Simplification from twice-daily to once-daily darunavir/ritonavir in a randomized trial among HIV-infected persons with HIV-1 RNA suppression on antiretroviral therapy.
    Huhn GD, Sigman A, Livak B.
    Antivir Ther; 2015 Sep; 20(8):849-54. PubMed ID: 25881614
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study.
    Blanco JL, Rojas J, de Lazzari E, Inciarte A, Subirana M, Callau P, Martinez-Rebollar M, Laguno M, Mallolas J, de la Mora L, Torres B, Gonzalez-Cordón A, Martinez E.
    J Antimicrob Chemother; 2022 Jun 29; 77(7):1974-1979. PubMed ID: 35512339
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice.
    Moltó J, Santos JR, Negredo E, Miranda C, Videla S, Clotet B.
    J Antimicrob Chemother; 2007 Aug 29; 60(2):436-9. PubMed ID: 17556354
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Long-term efficacy and safety of once-daily fosamprenavir 1400 mg boosted by ritonavir 100 mg: the BOLD100 study.
    Blick G, Greiger-Zanlungo P, Gretz S, Han J, Dupree D, Garton T, Yau LH, Wine BC, Pakes GE, Boosting Once-daily Lexiva Delivery with ritonavir 100 mg QD [BOLD100] Study Team.
    Int J STD AIDS; 2012 Mar 29; 23(3):e18-22. PubMed ID: 22581890
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V, García-Gasco P, Vispo E, Ruiz-Sancho A, Blanco F, Martín-Carbonero L, Rodríguez-Novoa S, Morello J, de Mendoza C, Rivas P, Barreiro P, González-Lahoz J.
    J Antimicrob Chemother; 2008 Jan 29; 61(1):200-5. PubMed ID: 17999977
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of unboosted atazanavir in combination with lamivudine and didanosine in naive HIV type 1 patients in Senegal.
    Landman R, Diallo MB, Gueye NF, Kane CT, Mboup S, Fall MB, Ndiaye B, Peytavin G, Bennai Y, Benalycherif A, Girard PM, Sow PS.
    AIDS Res Hum Retroviruses; 2010 May 29; 26(5):519-25. PubMed ID: 20455760
    [Abstract] [Full Text] [Related]

  • 40. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Boonyaprawit P.
    Antivir Ther; 2005 May 29; 10(8):911-6. PubMed ID: 16430196
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.